NEW YORK (GenomeWeb News) – Roche today announced that it has teamed with the Innovative Medicines Initiative to lead a consortium of industry and academic partners that will use stem cells for drug discovery research.

The project, called StemBANCC, will be initiated and coordinated by Roche, managed by Oxford University, and include 10 pharmaceutical companies and 23 academic institutions. Researchers involved in the effort will use human induced pluripotent stem cells as tools for drug discovery with the goal of developing human disease models and enhancing drug development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.